# Sinovac Biotech Ltd (SVA)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/sinovac-biotech-ltd/ JSON: https://steadybase.io/company/sinovac-biotech-ltd.json Checked Nov 21, 2026. Latest filing read: Jun 5, 2026.

## Company

- Legal name: SINOVAC BIOTECH LTD
- Ticker: SVA (Nasdaq)
- SEC CIK: 0001084201
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Beijing
- Fiscal year ends: December 31
- SEC filer category: Accelerated filer
- Website: sinovac.com
- Investor relations: https://www.sinovac.com/en-us/Investors

## Key facts

- Revenue: $386.0M for the fiscal year ended Dec 31, 2025 (20-F filed Jun 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/0001193125-26-258534-index.html
- Operating income: -$490.1M for the fiscal year ended Dec 31, 2025 (20-F filed Jun 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/0001193125-26-258534-index.html
- Net income: -$198.8M for the fiscal year ended Dec 31, 2025 (20-F filed Jun 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/0001193125-26-258534-index.html
- SG&A: $333.0M for the fiscal year ended Dec 31, 2025 (20-F filed Jun 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/0001193125-26-258534-index.html
- Employees: 2,602 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm
- Shares outstanding: 71,860,702 as of Dec 31, 2025 (20-F filed Jun 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/0001193125-26-258534-index.html
- Auditor: Zhonghua Certified Public Accountants LLP, Shanghai, China, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm

## Business

We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus..

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $386.0M | -$490.1M | -$198.8M | $333.0M |
| Dec 31, 2024 | $361.4M | -$505.5M | $40.7M | $420.9M |
| Dec 31, 2023 | $470.2M | -$714.0M | -$13.5M | $598.3M |
| Dec 31, 2022 | $1.5B | -$509.0M | $14.5M | $836.1M |
| Dec 31, 2021 | $19.4B | $17.6B | $8.1B | $602.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/sinovac-biotech-ltd.json

## Officers and directors

- Yin Weidong, Chief Executive Officer. LinkedIn: https://linkedin.com/in/yin-weidong-44971b218. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1084201/000121390026029794/0001213900-26-029794-index.htm
- Nan Wang, Chief Financial Officer. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1084201/000121390026029883/0001213900-26-029883-index.htm
- Guang (Helen) Yang, Chief Business Officer. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1084201/000121390026029894/0001213900-26-029894-index.htm
- Qiang (Nmn) Gao, Chief Operation Officer. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1084201/000121390026029885/0001213900-26-029885-index.htm
- Jing (Nmn) Li, VP, Quality and Production. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1084201/000121390026029904/0001213900-26-029904-index.htm

## Recent 8-K events

- Oct 26, 2000: Item 4, Item 4. Source: https://www.sec.gov/Archives/edgar/data/1084201/000101968700001504/0001.txt

## Latest filings

- 8-K filed Oct 26, 2000: https://www.sec.gov/Archives/edgar/data/1084201/000101968700001504/0001.txt
- 20f filed Jun 5, 2026: https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

